Showing 1411-1420 of 1614 results for "".
- New Technology, Greater Patient Awareness Will Help Drive Gains in Premium Cataract Surgeryhttps://modernod.com/news/new-technology-greater-patient-awareness-will-help-drive-gains-in-premium-cataract-surgery/2480489/Gains in the premium cataract surgery market over the next 5 years will be driven by technological improvements, growing value awareness among patients, declining reimbursement in the public
- Centricity Vision Names Todd Pinkney Chief Commercial Officer; Launches New Campaign for Zepto Cataract Surgical Platformhttps://modernod.com/news/centricity-vision-names-todd-pinkney-chief-commercial-officer-launches-new-campaign-for-zepto-cataract-surgical-platform/2480437/Centricity Vision announced that Todd Pinkney has been named chief commercial officer (CCO) and will lead global commercialization of the Zepto Platform. "We're confident that Zepto will have a huge impact on the cataract surgery market," Mr. Pinkney said.
- I-MED Pharma Set to Launch its Dry Eye Product Portfolio in the UShttps://modernod.com/news/i-med-pharma-set-to-launch-its-innovative-dry-eye-product-portfolio-in-the-us/2480408/I-MED Pharma USA announced it is bringing its dry eye product portfolio to the US market and will sell directly to eye care professionals. The dry eye portfolio includes I-DROP artificial tears, I-LID ’N LASH ocular hy
- CooperVision Specialty EyeCare Launches Optimized Pupil Optics for Onefit MED and Onefit MED+ Scleral Lenseshttps://modernod.com/news/coopervision-specialty-eyecare-launches-optimized-pupil-optics-for-onefit-med-and-onefit-med-scleral-lenses/2480394/CooperVision Specialty EyeCare announced the launch of Optimized Pupil Optics (OPO) for its Onefit MED and Onefit MED+ scleral contact lenses to eye care providers (ECPs) in the United States and Canada. The new high precision design option—which is supported by an
- Hoya Vision Care and Haag-Streit Partner to Combat Myopiahttps://modernod.com/news/hoya-vision-care-and-haag-streit-partner-to-combat-myopia/2480322/Hoya Vision Care announced a strategic partnership with Haag-Streit to help address the global rise of myopia in children. The global sales and marketing agreement creates a preferred partnership between Hoya Vision Care and Haag-Streit to provide eye care professionals (ECPs) with Lenstar M
- Ludwin Monz Stepping Down as CEO of Carl Zeiss Meditechttps://modernod.com/news/ludwin-monz-stepping-down-as-ceo-of-carl-zeiss-meditec/2480316/President and CEO of Carl Zeiss Meditec AG Ludwin Monz, PhD, announced that he will not be accepting another term in office, and will be stepping down from his postion effective December 31, 2021. The supervisory board has appointed Markus Weber, PhD, as the new President and
- Neurolens Names Pierre Bertrand Chief Executive Officerhttps://modernod.com/news/neurolens-names-pierre-bertrand-chief-executive-officer/2480277/Neurolens has named Pierre Bertrand Chief Executive Officer. A senior executive with experience in the eye care space, Mr. Bertrand brings more than 20 years of marketing and strategic expertise to Neurolens. In his role as Chief Executive Officer, Mr. Bertrand will be respons
- Visus Unveils Additional Ophthalmic Drug Candidates for Corneal Wound Healing, Glaucoma and AMDhttps://modernod.com/news/visus-unveils-additional-ophthalmic-drug-candidates-for-corneal-wound-healing-glaucoma-and-amd/2480276/During its inaugural Capital Markets Day in New York City, Visus Therapeutics unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD). Additionally, the company introduced a novel drug
- Luminopia One Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial for Amblyopiahttps://modernod.com/news/luminopia-one-demonstrates-safety-and-efficacy-in-phase-3-pivotal-trial/2480274/Luminopia announced the publication of positive phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One. Published in Ophthalmology, the study was conducted at 21 academic and community sites in the U.S., in which childre
- Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sinteticahttps://modernod.com/news/harrow-health-acquires-patented-ophthalmic-surgical-drug-candidate-from-sintetica/2479416/Harrow Health, Inc. announced that it has entered into an agreement with Sintetica to acquire the marketing and supply rights in the U.S. and Canada for AMP 100, a patented ophthalmic surgical drug candidate. When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic interven